Evidence map›Paper›PMID 26545583›Full record

ArticleBMC cancer2015

MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer.

Bhavana V Chapman, Abigail I Wald, Parvez Akhtar, Ana C Munko, Jingjing Xu, Sandra P Gibson, Jennifer R Grandis, Robert L Ferris, Saleem A Khan

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bhavana V ChapmanDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. bsv4@pitt.edu.
Abigail I WaldDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. waldai@upmc.edu.
Parvez AkhtarDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. paa13@pitt.edu.
Ana C MunkoDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. acv12@pitt.edu.
Jingjing XuDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. Jix58@pitt.edu.
Sandra P GibsonDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, 15216, USA. spoveda@pitt.edu.
Jennifer R GrandisDepartment of Otolaryngology, University of Pittsburgh and University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA. jennifer.grandis@ucsf.edu.
Robert L FerrisDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, 15216, USA. ferrrl@upmc.edu.
Saleem A KhanDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA. khan@pitt.edu.
University of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

Role of MicroRNA 363 in HPV-positive oral cancerR21DE021881 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KHAN, SALEEM A. · 2012 to 2013
$405k
Howard Hughes Medical InstituteNIDCR NIH HHS 1R21 DE021881NIDCR NIH HHS R21 DE021881
6 · The paper itself

Abstract

backgroundSquamous cell carcinoma of the head and neck (SCCHN) remains a prevalent and devastating disease. Recently, there has been an increase in SCCHN cases that are associated with high-risk human papillomavirus (HPV) infection. The clinical characteristics of HPV-positive and HPV-negative SCCHN are known to be different but their molecular features are only recently beginning to emerge. MicroRNAs (miRNAs, miRs) are small, non-coding RNAs that are likely to play significant roles in cancer initiation and progression where they may act as oncogenes or tumor suppressors. Previous studies in our laboratory showed that miR-363 is overexpressed in HPV-positive compared to HPV-negative SCCHN cell lines, and the HPV type 16-E6 oncoprotein upregulates miR-363 in SCCHN cell lines. However, the functional role of miR-363 in SCCHN in the context of HPV infection remains to be elucidated.

methodsWe analyzed miR-363 levels in SCCHN tumors with known HPV-status from The Cancer Genome Atlas (TCGA) and an independent cohort from our institution. Cell migration studies were conducted following the overexpression of miR-363 in HPV-negative cell lines. Bioinformatic tools and a luciferase reporter assay were utilized to confirm that miR-363 targets the 3'-UTR of myosin 1B (MYO1B). MYO1B mRNA and protein expression levels were evaluated following miR-363 overexpression in HPV-negative SCCHN cell lines. Small interfering RNA (siRNA) knockdown of MYO1B was performed to assess the phenotypic implication of reduced MYO1B expression in SCCHN cell lines.

resultsMiR-363 was found to be overexpressed in HPV-16-positive compared to the HPV-negative SCCHN tumors. Luciferase reporter assays performed in HPV-negative JHU028 cells confirmed that miR-363 targets one of its two potential binding sites in the 3'UTR of MYO1B. MYO1B mRNA and protein levels were reduced upon miR-363 overexpression in four HPV-negative SCCHN cell lines. Increased miR-363 expression or siRNA knockdown of MYO1B expression reduced Transwell migration of SCCHN cell lines, indicating that the miR-363-induced migration attenuation of SCCHN cells may act through MYO1B downregulation.

conclusionsThese findings demonstrate that the overexpression of miR-363 reduces cellular migration in head and neck cancer and reveal the biological relationship between miR-363, myosin 1b, and HPV-positive SCCHN.

Indexed as

RNA Interference3' Untranslated RegionsAgedBase SequenceBinding SitesCell Line, TumorCell MovementFemaleGene ExpressionGene Knockdown TechniquesHead and Neck NeoplasmsHumansMaleMicroRNAsMiddle AgedMyosin Type I3' Untranslated RegionsMicroRNAsMIRN363 microRNA, humanMYO1B protein, humanMyosin Type IRNA, Messenger

Identifiers

PMID26545583
PMCPMC4635687
OpenAlexW2166499650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.